Tirzepatide
- Generic Name
- Tirzepatide
- Brand Names
- Mounjaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2023788-19-2
- Unique Ingredient Identifier
- OYN3CCI6QE
- Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...
- Indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
New weight-loss treatment becomes first FDA-approved drug for sleep apnea
The FDA approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, the first drug to directly treat the disorder. The approval is for moderate to severe obstructive sleep apnea in adults with obesity, potentially expanding the market and strengthening Lilly’s case with insurers. Zepbound, a GLP-1 agonist, also reduces food cravings and slows stomach emptying, with trial data showing it eased breathing difficulties and lowered sleep apnea biomarkers.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea
Eli Lilly's weight loss drug Zepbound approved by FDA for treating obesity and moderate-to-severe obstructive sleep apnea (OSA), expanding its use and potentially insurance coverage in the U.S. Zepbound, first approved for obesity, is now cleared for OSA, a common sleep-related breathing disorder affecting 80 million in the U.S., with 85% undiagnosed. Eli Lilly expects to launch the drug for OSA early next year, with clinical trials showing Zepbound reduced OSA severity and resolved the condition in nearly half of patients.
THIS weight-loss drug becomes first to gain approval for treating sleep apnea
The FDA approved Eli Lilly's Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, marking the first drug for the condition. Zepbound, containing tirzepatide, aids in reducing food cravings and stomach emptying, with trials showing it resolved the disorder in up to 52% of patients. Lilly's shares rose 1.14% post-approval.
Novo Nordisk's share plunges 19.5% post release of weight loss drug CagriSema's trial results
Experimental obesity drug CagriSema by Novo Nordisk helped overweight patients lose 22.7% of their weight in a late-stage trial, but results were 25% lower than expected. The drug combines semaglutide with cagrilintide to suppress hunger and control blood glucose. Novo's share price fell 19.5% following the announcement.
Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints
Novo Nordisk's stock dropped 21% after its obesity drug CagriSema showed less weight loss than expected, averaging 22.7%. Competitor Eli Lilly's stock rose 5%.
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
Novo Nordisk's CagriSema obesity drug trial results showed 22.7% weight loss, below the expected 25%, causing a $125 billion market value loss. The drug combines semaglutide and cagrilintide, aiming to be a successor to Wegovy. Despite the disappointment, Novo Nordisk plans a new trial and regulatory submission by 2025.
Novo Nordisk shares tank 20% after latest obesity drug disappoints
Novo Nordisk's next-gen obesity treatment CagriSema showed less weight loss than expected, causing a 20% share drop and £70B market value loss. The treatment, combining semaglutide and cagrilintide, induced 22.7% weight loss vs. 22.5% by Lilly's Mounjaro. Both firms race to develop oral drugs by 2025, aiming to improve weight loss and reduce side effects. The weight loss market is projected to grow from $24B in 2023 to over $100B by 2030.
Eli Lilly (LLY) stock: Why It's a strong buy amid breakthrough developments
Eli Lilly and Co. (LLY) is a strong buy due to its promising Alzheimer’s drug Donanemab, leadership in diabetes care, robust financial growth, strategic acquisitions, positive analyst sentiment, and increasing demand for specialty drugs.
US FDA says Lilly's weight-loss drug shortage is resolved
FDA says no shortage of Eli Lilly's weight loss and diabetes drugs, allowing compounding pharmacies to continue making cheaper copies for 60-90 days. Lilly warns against marketing unapproved versions of tirzepatide. Novo Nordisk's Wegovy still in shortage. Compounding pharmacies argue shortage persists.
Drugs like Ozempic now make up 5% of prescriptions in the US
Eli Lilly plans to test its GLP-1 drug, tirzepatide, for addiction treatment. The drug may counteract hedonistic pursuits, reducing opioid overdose risk. It also improved sleep apnea symptoms and reduced all-cause mortality, making it a candidate for life-extension research.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath